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Abstract
Nucleoside transporters are divided into two families, the sodium-dependent, concentrative solute carrier family
28 (SLC28) and the equilibrative, solute carrier family 29 (SLC29). The endogenous substrates are typically
nucleosides, although some family members can also transport nucleobases and organic cations.
Contents
This is a citation summary for SLC28 and SLC29 families of nucleoside transporters in the Guide to
Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of
citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant
sections of the database which are given here under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb
curators.
Database links
SLC28 and SLC29 families of nucleoside transporters
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=149
    SLC28 family
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=215
        Transporters
                CNT1(Sodium/nucleoside cotransporter 1)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1114
                CNT2(Sodium/nucleoside cotransporter 2)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1115
                CNT3(Solute carrier family 28 member 3)
1
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1116
    SLC29 family
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=216
        Transporters
                ENT1(Equilibrative nucleoside transporter 1)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1117
                ENT2(Equilibrative nucleoside transporter 2)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1118
                ENT3(Equilibrative nucleoside transporter 3)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1119
                PMAT(Plasma membrane monoamine transporter)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1120
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